In 2 molecules were presented, modifications of Aspirin bound to the COX-2 enzyme and Simeprevir bound to the SARS-Cov-2 3CL Mpro main protease, to demonstrate the use of the software Ligand GA. The analysis generated modifications of both molecules that have higher binding interaction and tighter fits to their respective protein cavities (binding sites), COX-2 and SARS-Cov-2 3CL Mpro. The modifications of Aspirin resulted in small molecules of >2x binding interactions and without any seeming structural oddities. Simeprevir to start out with is large and flexible, as were the Ligand GA modified molecules (ADME constraints were not used with that molecule's modifications).